Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple Sclerosis

IF 20.4 1区医学 Q1 CLINICAL NEUROLOGY

JAMA neurology Pub Date : 2025-03-31 DOI:10.1001/jamaneurol.2025.0337

Liza M. Y. Gelissen, Martijn T. Wijburg, Eva M. M. Strijbis, Bob W. van Oosten, Brigit A. de Jong, Bernard M. J. Uitdehaag, Theo Rispens, Mariet C. W. Feltkamp, Zoé L. E. van Kempen, Joep Killestein

引用次数: 0

Abstract

This cross-sectional study examines the increase in positive results for John Cunningham virus antibodies and higher risk for progressive multifocal leukoencephalopathy among patients with multiple sclerosis receiving natalizumab.

查看原文本刊更多论文

纳塔利单抗治疗多发性硬化症患者新约翰·坎宁安病毒抗体测定的准确性

本横断面研究探讨了接受natalizumab治疗的多发性硬化症患者John Cunningham病毒抗体阳性结果的增加和进行性多灶性白质脑病的高风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JAMA neurology CLINICAL NEUROLOGY-

CiteScore

41.90

自引率

1.70%

发文量

250

期刊介绍： JAMA Neurology is an international peer-reviewed journal for physicians caring for people with neurologic disorders and those interested in the structure and function of the normal and diseased nervous system. The Archives of Neurology & Psychiatry began publication in 1919 and, in 1959, became 2 separate journals: Archives of Neurology and Archives of General Psychiatry. In 2013, their names changed to JAMA Neurology and JAMA Psychiatry, respectively. JAMA Neurology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.